On Nov 04, 2017, Hangzhou Sciwind Biosciences Co.,Ltd establish, and the unveiling ceremony of its BeiJing R&D Center held solemnly in BeiJing.

2017-11-06 17:00:31 0

Fight to NASH, Liver Fibrosis and Cirrhosis!

Hangzhou Sciwind Biosciences Co.,Ltd establish, and unveil its BeiJing R&D Center


On Nov 04HangZhou Sciwind Biosciences Co.,LtdIn short : Sciwind Biosciences ) establish. The unveiling ceremony of its BeiJing R&D Center and The signing ceremony of the scientific consultant held solemnly in BeiJing. At the ceremony, WeiLai professor is formally hired as a scientific consultant, and make an excellent academic reports.

Sciwind Biosciences is leded by Dr. PanHai who is“the Recruitment Program of Global Experts”and formed by Kawin technology R&D team with extensive experience in drug development. Our company is founded in HangZhou in August 2017, devote to develop new drugs with independent intellectual property rightsand introduce two strategic investment partners of ShiYu capital and HaiBang venture initially.

The company adheres to the idea of "Science First, Work Hard, Gentlemen Achieve". View the whole world and serve China. “Fight to NASH, Liver Fibrosis and Cirrhosis, become the pioneer in this field”Dr. PanHai, chairman & CEO of Sciwind Biosciences, explain the company's vision : At the beginning of establishmentSciwind Biosciences has positioned itself as an international company of innovative drug development for metabolic critical diseases, the breakthrough is NASH, Liver Fibrosis and Liver Cirrhosis. The confidence We have positioned such a high level, comes from the company has a technical team of high-level talents and a scientific consultant team with an international level.

the scientific consultant WeiLai Professor, appointed at ceremony ,is the director of Peking University Liver Disease Research Institute, as well as the sixth chairman and the leader of the NASH group of the Chinese Medical Association Branch of Hepatology. In the ceremony report, WeiLai Professor point out : The population of Non-alcoholic Fatty Liver (NAFLD) increases at a rate of 3% to 4% per year, of which 25% will develop into Non-alcoholic Steatohepatitis (NASH) within 3 years. NASH can develop into fibrosis within 7 years, and 1% to 4% of the cirrhosis develop into liver cancer each year. NASH is becoming the leading liver disease. The global population of NAFLD exceeds 600 million, and China is 200 million, accounting 10% to 30% of the total population. The demand of NASH medical market is great in the future.

With the change of lifestyle, the patients of hyperglycemia, hyperlipidemia and hypertension increase greatly, which will accelerate the progress of NASH greatly. It is expected that the main reason of liver transplantation in Europe and America in 2020, is Liver Cirrhosis caused by NASH. There are no drugs to treat NASH, Liver Fibrosis and Cirrhosis transformed from NASH at present, Drug development for NASH is one of the hotspots in the liver disease field, Combined treatment with different target drugs is the development trend of treating NASH drugs.

“The market for NASH in Europe and United States will reach at least ten billion dollars in 2025, The number of NASH patients is huge in China, and the market of NASH is very considerable in the future. The fields of NASH, Liver Fibrosis and Cirrhosis have a brilliant future” PanHai said :“Enough wide field of treatment and huge market, that's why we chose NASH as our breakthrough.”

The founder of Sciwind Bioscience is Dr. PanHai, had worked many years in Amgen, the world's largest biopharmaceutical company. Pan has engaged in the research of new drugs for liver diseases for a long time ,and led the team achieve two items registration applications of type 1 innovative drugs to treat hepatitis curative, which have been listed as a priority evaluation procedure by CFDA at present. Now, Sciwind Bioscience have accumulated profound R&D experience and abundant clinical resources in the field of liver diseases, and developing drugs in three pathways of reducing NASH, Inflammation and Fibrosis independently, In addition, we are actively introducing foreign projects that are already in clinical stage. Strive to become a leading enterprise of innovative drugs with sustainable development in short term, and bring affordable innovative drugs to the masses of patients as soon as possible.